These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33844796)

  • 1. [Carbapenemases produced by Carbapenem-resistant Pseudomonas aeruginosa isolated from hospitals in Chile].
    Costa JSTD; Lima CA; Vera-Leiva A; San Martin Magdalena I; Bello-Toledo H; Domínguez Yévenes M; Opazo-Capurro A; Mella Montecinos S; Quezada-Aguiluz M; González-Rocha G;
    Rev Chilena Infectol; 2021 Feb; 38(1):81-87. PubMed ID: 33844796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.
    Rizek C; Fu L; Dos Santos LC; Leite G; Ramos J; Rossi F; Guimaraes T; Levin AS; Costa SF
    Ann Clin Microbiol Antimicrob; 2014 Sep; 13():43. PubMed ID: 25179208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular Analysis of Antibiotic Resistance in CarbapenemResistant Pseudomonas aeruginosa Isolates Isolated from Clinical Samples].
    Altan G; Rakici E; Özgümüş OB
    Mikrobiyol Bul; 2024 Apr; 58(2):148-170. PubMed ID: 38676583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying bla
    PÉrez-VÁzquez M; Sola-Campoy PJ; Zurita ÁM; Ávila A; GÓmez-Bertomeu F; SolÍs S; LÓpez-Urrutia L; GÓnzalez-BarberÁ EM; Cercenado E; Bautista V; Lara N; Aracil B; Oliver A; Campos J; Oteo-Iglesias J;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106026. PubMed ID: 32450200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey.
    Malkoçoğlu G; Aktaş E; Bayraktar B; Otlu B; Bulut ME
    Microb Drug Resist; 2017 Apr; 23(3):328-334. PubMed ID: 27326514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
    Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal Distribution and Its Association With the Carbapenem Resistance Mechanisms of Carbapenem-Non-Susceptible
    Kim N; Ko SY; Park SY; Kim SY; Lee DE; Kwon KT; Kim YK; Lee JC
    Ann Lab Med; 2024 Sep; 44(5):410-417. PubMed ID: 38433574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.
    McCracken MG; Adam HJ; Blondeau JM; Walkty AJ; Karlowsky JA; Hoban DJ; Zhanel GG; Mulvey MR;
    J Antimicrob Chemother; 2019 Aug; 74(Suppl 4):iv32-iv38. PubMed ID: 31505643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
    Kim CH; Kang HY; Kim BR; Jeon H; Lee YC; Lee SH; Lee JC
    J Microbiol; 2016 Jan; 54(1):44-49. PubMed ID: 26727901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa.
    Atrissi J; Milan A; Bressan R; Lucafò M; Petix V; Busetti M; Dolzani L; Lagatolla C
    Microbiol Spectr; 2021 Oct; 9(2):e0118621. PubMed ID: 34585948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the resistance mechanism and homology of carbapenems-resistant Pseudomonas aeruginosa].
    Liu Y; Deng Q; Yu Y; Cao X; Xu Q; Wan L
    Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):15-20. PubMed ID: 24684984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular surveillance of carbapenemase-producing
    Schäfer E; Malecki M; Tellez-Castillo CJ; Pfennigwerth N; Marlinghaus L; Higgins PG; Mattner F; Wendel AF
    Antimicrob Resist Infect Control; 2019; 8():208. PubMed ID: 31893042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Carbapenemase Encoding Gene and Resistance to Cefiderocol in Hospital and Community eXtensive Drug Resistance and Carbapenem-Resistant
    Benzaarate I; El Otmani F; Khazaz A; Timinouni M; Bourjilat F; Bogaerts P; Huang TD; Nayme K
    Foodborne Pathog Dis; 2023 Oct; 20(10):460-466. PubMed ID: 37616567
    [No Abstract]   [Full Text] [Related]  

  • 15. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of rmtD1 gene in clinical isolates of Pseudomonas aeruginosa carrying bla
    Costa-Júnior SD; da Silva AMCM; Niedja da Paz Pereira J; da Costa Lima JL; Cavalcanti IMF; Maciel MAV
    Braz J Microbiol; 2021 Dec; 52(4):1959-1965. PubMed ID: 34420185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predominance of carbapenem-resistant Pseudomonas aeruginosa isolates carrying blaIMP and blaVIM metallo-β-lactamases in a major hospital in Costa Rica.
    Toval F; Guzmán-Marte A; Madriz V; Somogyi T; Rodríguez C; García F
    J Med Microbiol; 2015 Jan; 64(Pt 1):37-43. PubMed ID: 25355933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of carbapenem resistance mechanism in clinical isolates of Pseudomonas aeruginosa isolated from burn patients, in Tehran, Iran.
    Mirsalehian A; Kalantar-Neyestanaki D; Taherikalani M; Jabalameli F; Emaneini M
    J Epidemiol Glob Health; 2017 Sep; 7(3):155-159. PubMed ID: 28756823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. aeruginosa high-risk clones with VIM-5- and IMP-7-type carbapenemases in a tertiary hospital.
    Çekin ZK; Dabos L; Malkoçoğlu G; Fortineau N; Bayraktar B; Iorga BI; Naas T; Aktaş E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115174. PubMed ID: 32980808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.